NIH begins ZMapp trial; Sanofi nears EU nod with new insulin;

@FierceBiotech: From @FiercePharmAsia, Novartis' Japan unit hit with a 15-day sales ban. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vitae slammed as another BACE inhibitor trips and Boehringer halts Alzheimer's study. Report | Follow @JohnCFierce

@DamianFierce: While $MRK and $ACT embrace antibiotics, $AZN is tiptoeing out. Report | Follow @DamianFierce

> The National Institutes of Health has kicked off its clinical trial of Mapp Biopharmaceutical's ZMapp, a promising treatment for Ebola. More

> Sanofi's ($SNY) Toujeo, a long-acting insulin, secured an EU recommendation just days after picking up FDA approval, stoking the companies hopes of usurping the soon-to-come-off-patent Lantus. Story

> In a late-stage trial, the combination of Bristol-Myers Squibb's ($BMY) daclatasvir and Gilead Sciences' ($GILD) Sovaldi charted a 97% cure rate for hepatitis C patients who also have HIV. News

Medical Device News

@FierceMedDev: Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Scientific launches upgraded endoscope, says it will reduce repeat procedures. Article | Follow @VarunSaxena2

@EmilyWFierce: Vigilant Biosciences reels in $5.5M for oral cancer test. More from FierceDiagnostics | Follow @EmilyWFierce

> Nikon to buy optical imaging player Optos for $400M in med tech expansion bid. Story

> UnitedHealth to require prior authorization for gynecological procedures amid morcellator pushback. More

> Device for remote and autonomous management of Parkinson's being tested in Europe. Article

Pharma News

@FiercePharma: ICYMI from FiercePharmaManufacturing: Impax reports significant jump in revenues as it gets plant problems behind it. Article | Follow @FiercePharma

@EricPFierce: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Pfizer, Novartis get MenB ACIP nod--but not the one they're really after. More from FierceVaccines | Follow @CarlyHFierce

> Pfizer, Novartis: CDC's MenB nod is too narrow. Item

> Sanofi's Toujeo gets the love from EU regulators that FDA withheld. Story

> Gilead looks overseas to guard profits for hep C blockbuster Sovaldi. Article

Suggested Articles

French biotech Genfit is cutting its way out of its phase 3 NASH disaster in the summer and cresting two new units.

The FDA has expanded its investigation to include data from clinical trials of prophylactics based on the same viral vector platform.

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.